AVIR - Company ID 0001593899
The table below shows Atea Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $41.13M | $38.35M | $32.27M | $29.58M | $26.16M | $34.70M |
| SG&A |
Atea Pharmaceuticals, Inc. reported annual revenue of $351.37M for fiscal year 2021. That is up 622.5% from $48.63M in fiscal 2020. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.87M |
| $7.22M |
| $9.07M |
| $9.46M |
| $11.04M |
| $12.22M |
| Operating income | -$48.01M | -$45.57M | -$41.34M | -$39.04M | -$37.20M | -$46.92M |
| Income tax | $50.00K | $196.00K | $207.00K | $203.00K | $226.00K | $243.00K |
| Net income | -$45.44M | -$42.05M | -$37.16M | -$34.27M | -$31.15M | -$40.52M |
| EPS (diluted) | -$0.57 | -$0.53 | -$0.44 | -$0.40 | -$0.37 | -$0.48 |